longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

"Performance" Baiyunshan's annual net profit is 2.983 billion RMB, an increase of 5.2%, with a final dividend of 0.45 yuan

AASTOCKS
Mar 22, 2026 at 08:53 AM

BAIYUNSHAN PH (00874.HK) announced its 2025 annual results, with operating revenue of RMB 77.656 billion, an increase of 3.6% year-on-year. The net profit attributable to shareholders was RMB 2.983 billion, a growth of 5.2%, with earnings per share of RMB 1.835. A final dividend of 45 cents was declared

Source: AASTOCKS The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

Recommended Readings

  • Apr 22, 2026 at 10:30 AMInnovative Drug Revenue Share Surpasses 60% for First Time, HENGRUI PHARMA Q1 Revenue Hits 8.14 Billion Yuan, Net Profit…
  • Apr 2, 2026 at 07:24 PMOfficial Announcement: US Maintains 50% Metal Tariffs, Imposes 25% Tariffs on Some Finished Products, 100% on Patented D…
  • Mar 27, 2026 at 05:24 AMBuying Platforms, Selling Pipelines: Deconstructing the Innovation Logic of SINO BIOPHARM
  • Mar 26, 2026 at 07:03 AMThe Reality and Illusion of "AI Drug Discovery" XTALPI's Turnaround
  • Mar 25, 2026 at 07:02 AMStronger After No Longer "Flying Solo"

Related Stocks

GYBYS

GYBYS

SH600332

BAIYUNSHAN PH

BAIYUNSHAN PH

HK00874

Guotai SSE STAR Brand Name Drug ETF

Guotai SSE STAR Brand Name Drug ETF

SH589720

LongbridgeAI